Tumgik
#DNAsequence
chryssy67 · 2 years
Text
Nature & the Cosmos are made up of intricate PATTERNS !!
Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media
17 notes · View notes
bosses-stay-flawless · 8 months
Text
Tumblr media Tumblr media Tumblr media Tumblr media
When you read the words & images VS when you read the ENERGY.
Energy allows you to understand more intricately and much more intimately.
Learn to rely on your ability to read energy and don’t just rely solely on your senses.
Learning to see clearly…
#aftertherain #7generations #ascensioncodes
#dnasequences #healingthefrequency
7 notes · View notes
samartoficial · 6 years
Photo
Tumblr media
Vida 🌌 . . Obrigado maia uma vez pela confiança Mi! @migigich . . #tattoo #tatuagem #watercolor #watercolortattoo #aquarela #tatuagemaquarela #colors #cores #life #dna #dnasequence #treetattoo #tree #treeoflife #samartist #art #artist #artwork #awesome #tattoooftheday #inkinked #inkedmag #usoelectricink #electricink #electricinkpen @electricink @paulo_angotti @electricinkbr
3 notes · View notes
arktrux · 3 years
Photo
Tumblr media
the DNA #Contemporary art #art #abstraxt #meaning in this #installation #thedna of the #owners #theduke and #duchessofdevonshire #comissioned #jacobvanderbeugel #ceramic #panel with their #dnasequences #fantastic #chastworthhouse #june2021 (at Chatsworth House) https://www.instagram.com/p/CQPGEgrBPd-/?utm_medium=tumblr
0 notes
phagethemage · 6 years
Text
Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media Tumblr media
@goblinmancrybaby you done did it now
@just-a-little-lost-cause @quelana @rabbureblogs @m-a-x-x-x-i-e @lysallana @dnasequence @queuespam @courierchell @kranyu @shalakazka
15 notes · View notes
tppanzstop-blog · 6 years
Text
Blueprint. How DNA makes us who we are - Robert Plomin.
Blueprint. How DNA makes us who we are – Robert Plomin.
The DNA revolution has recently given us the power to predict our psychological strengths and weaknesses from birth. This is a gamechanger that has far reaching implications for psychology, for society and for each and every one of us.
For most of the twentieth century environmental factors were called nurture because the family was thought to be crucial in determining who we become. Genetic…
View On WordPress
0 notes
HPV Testing And Pap Test Market Share, Trends and Segment To 2024: Grand View Research, Inc.
The global Human Papillomavirus (HPV) testing and Pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). 
In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. 
A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients. 
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings from the report suggest:
·         The cervical cancer screening segment dominated the market in 2015 owing to the introduction of advanced technologies for the screening and detection of cervical cancer. For instance, in May 2016,Hologic Inc. determined that HPV and Pap co-testing was the most effective in the screening of cervical cancer.
·         The laboratories segment dominated the HAV and Pap test market in 2015 owing to the increased performance in the diagnosis of cervical cancer cases. As per the CDC statistics, approximately 21.7 million tests were performed in the U.S.; hence,the hospitalssegmentis expected to witnessa rapid growthin the coming years due to the increasing number of diagnostic tests performed in-house and also the availability of advanced technologies.
·         In 2015, North America held the largest share in terms of revenue owing to the continual introduction ofinnovated technologies to improve patient care and diagnosis. In addition, the high number of positive cases being detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has compelled the government to conduct awareness programmes about the early diagnosis and treatment of cervical cancer, which is a key factor for the large market share.
·         In April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides information regardingpatients’ risk of developing cervical cancer. The Cobas HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other high-risk HPVs from the cervical cell sample in women older than 25 years of age.
·         AsiaPacific is expected to grow at a high CAGR in the coming years. As per the cancer council, 61% of the Australian women are screened for cervical cancer every two years, out of which around 26% who have been detected throughthe normal Pap test undergo an early re-screening more often than the recommended two years of interval.
·         Some key players in the market are QiagenN. V., Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and Company.These market players are in the process of introducing tests to change the traditional methods of individual HPV and Pap tests and introducenewer techniques or devices to improve the efficiency and convenience.
·         For instance, in February 2016, Quest acquiredClinical Laboratory Partner’s outreach laboratory service business. This acquisition is expected to provide the patients a broader service network with better quality, affordability, and convenience. 
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the global HPV testing and Pap test market on the basis of type, application, end-use, and regions: 
HPV Testing and Pap Test Outlook by Type (Revenue, USD Million, 2013 – 2024)
·         Pap Test
·         HPV Test
HPV Testing and Pap Test Application Outlook (Revenue, USD Million, 2013 – 2024)
·         Cervical Cancer
·         Vaginal Cancer
HPV Testing and Pap Test End-use Outlook (Revenue, USD Million, 2013 – 2024)
·         Point-of-Care
·         Central Laboratories
·         Others
HPV Testing and Pap Test Regional Outlook (Revenue, USD Million, 2013 – 2024)
·         North America
·         U.S.
·         Canada
·         Europe
·         UK
·         Germany
·         Rest of Europe
·         Asia Pacific
·         India
·         Japan
·         China
·         Rest of Asia Pacific
·         Latin America
·         Brazil
·         Rest of Latin America
·         MEA
·         South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
For more information visit - www.grandviewresearch.com
0 notes
Text
HPV Testing And Pap Test Market is expected to reach USD 5.6 billion by 2024
The global Human Papillomavirus (HPV) testing and Pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). 
In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. 
A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients.
To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings from the study suggest:
The cervical cancer screening segment dominated the market in 2015 owing to the introduction of advanced technologies for the screening and detection of cervical cancer. For instance, in May 2016, Hologic Inc. determined that HPV and Pap co-testing was the most effective in the screening of cervical cancer.
The laboratories segment dominated the HAV and Pap test market in 2015 owing to the increased performance in the diagnosis of cervical cancer cases. As per the CDC statistics, approximately 21.7 million tests were performed in the U.S.; hence, the hospitalssegmentis expected to witness a rapid growthin the coming years due to the increasing number of diagnostic tests performed in-house and also the availability of advanced technologies.
In 2015, North America held the largest share in terms of revenue owing to the continual introduction ofinnovated technologies to improve patient care and diagnosis. In addition, the high number of positive cases being detected, along with the rising death toll (i.e., 2.6 in 1,00,000), has compelled the government to conduct awareness programmes about the early diagnosis and treatment of cervical cancer, which is a key factor for the large market share.
In April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides information regarding patients’ risk of developing cervical cancer. The Cobas HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other high-risk HPVs from the cervical cell sample in women older than 25 years of age.
Asia Pacific is expected to grow at a high CAGR in the coming years. As per the cancer council, 61% of the Australian women are screened for cervical cancer every two years, out of which around 26% who have been detected through the normal Pap test undergo an early re-screening more often than the recommended two years of interval.
Some key players in the market are QiagenN. V., Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and Company. These market players are in the process of introducing tests to change the traditional methods of individual HPV and Pap tests and introduce newer techniques or devices to improve the efficiency and convenience.
For instance, in February 2016, Quest acquired Clinical Laboratory Partner’s outreach laboratory service business. This acquisition is expected to provide the patients a broader service network with better quality, affordability, and convenience.
See More Reports of This Category: http://www.grandviewresearch.com/industry/healthcare
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Web: www.grandviewresearch.com
0 notes
HPV Testing And Pap Test Market is expected to reach USD 5.6 billion by 2024
The global Human Papillomavirus (HPV) testing and Pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). 
In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. 
A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients.
To request a sample copy or view summary of this report, click the link below: http://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings from the study suggest:
The cervical cancer screening segment dominated the market in 2015 owing to the introduction of advanced technologies for the screening and detection of cervical cancer. For instance, in May 2016, Hologic Inc. determined that HPV and Pap co-testing was the most effective in the screening of cervical cancer.
The laboratories segment dominated the HAV and Pap test market in 2015 owing to the increased performance in the diagnosis of cervical cancer cases. As per the CDC statistics, approximately 21.7 million tests were performed in the U.S.; hence, the hospitalssegmentis expected to witness a rapid growthin the coming years due to the increasing number of diagnostic tests performed in-house and also the availability of advanced technologies.
In 2015, North America held the largest share in terms of revenue owing to the continual introduction ofinnovated technologies to improve patient care and diagnosis. In addition, the high number of positive cases being detected, along with the rising death toll (i.e., 2.6 in 1,00,000), has compelled the government to conduct awareness programmes about the early diagnosis and treatment of cervical cancer, which is a key factor for the large market share.
In April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence of cancer-causing high-risk HPVs. It provides information regarding patients’ risk of developing cervical cancer. The Cobas HPV test is used to specifically identify HPV 16 and HPV 18as well as12 other high-risk HPVs from the cervical cell sample in women older than 25 years of age.
Asia Pacific is expected to grow at a high CAGR in the coming years. As per the cancer council, 61% of the Australian women are screened for cervical cancer every two years, out of which around 26% who have been detected through the normal Pap test undergo an early re-screening more often than the recommended two years of interval.
Some key players in the market are QiagenN. V., Hologic, Inc., Roche Holding AG, Abbott Laboratories, and Becton, Dickinson and Company. These market players are in the process of introducing tests to change the traditional methods of individual HPV and Pap tests and introduce newer techniques or devices to improve the efficiency and convenience.
For instance, in February 2016, Quest acquired Clinical Laboratory Partner’s outreach laboratory service business. This acquisition is expected to provide the patients a broader service network with better quality, affordability, and convenience.
See More Reports of This Category: http://www.grandviewresearch.com/industry/healthcare
About Grand View Research:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Web: www.grandviewresearch.com
0 notes
Text
HPV Testing and Pap Test Market  Is Projected To Reach $ 5.6 Billion By 2024: Grand View Research, Inc.
The global Human Papillomavirus (HPV) testing and Pap test market are expected to reach USD 5.6 billion by 2024, according to a new report by Grand View Research Inc.The market is majorly driven by the increasing number of cervical cancer cases, government initiatives, and the heightened awareness amongst women about cervical cancer. For instance, the CDC advocates cervical cancer screening tests for women above the age of 30 as it was found that the cervical cancers are rare in the age group, 20-30 years (2 in 100,000) as compared to the older age groups (16 in 100,000). 
In addition to carrying out awareness campaigns, the government and key industrial players are providing funding to universities for the development of enhanced technologies to facilitate effective screening, which would mitigate the incidence of late-stage cervical cancer. In this direction,in April 2014, the FDA approved the use of the HPV DNA test, also referred to as the Cobas HPV test (Roche Molecular Systems), as a primary screening test. 
A study conducted by the scientists of Hologic, Inc. and University of Pittsburgh Medical Center hasshownthe importance of combined testing (HPV and Pap) stating that the Paptest identifies cellular abnormalities and the HPV test detects suspicious viruses, hence improving the efficiency and providing the best results that are cost-effective and convenient to the patients. 
Browse full research report on HPV Testing and Pap Test Market: http://www.grandviewresearch.com/industry-analysis/hpv-testing-pap-test-market
Further key findings from the report suggest:
The     cervical cancer screening segment dominated the market in 2015 owing to     the introduction of advanced technologies for the screening and detection     of cervical cancer. For instance, in May 2016,Hologic Inc. determined that     HPV and Pap co-testing was the most effective in the screening of cervical     cancer.
The     laboratories segment dominated the HAV and Pap test market in 2015 owing     to the increased performance in the diagnosis of cervical cancer cases. As     per the CDC statistics, approximately 21.7 million tests were performed in     the U.S.; hence,the hospitalssegmentis expected to witnessa rapid growthin     the coming years due to the increasing number of diagnostic tests     performed in-house and also the availability of advanced technologies.
In     2015, North America held the largest share in terms of revenue owing to     the continual introduction ofinnovated technologies to improve patient     care and diagnosis. In addition, the high number of positive cases being     detected,along with the rising death toll (i.e., 2.6 in 1,00,000), has     compelled the government to conduct awareness programmes about the early     diagnosis and treatment of cervical cancer, which is a key factor for the     large market share.
In     April 2014, the FDA approved the use of the HPV DNA test, also referred to     as the Cobas HPV test. Roche introduced a test that detectsthe DNAsequence     of cancer-causing high-risk HPVs. It provides information     regardingpatients’ risk of developing cervical cancer. The Cobas HPV test     is used to specifically identify HPV 16 and HPV 18as well as12 other     high-risk HPVs from the cervical cell sample in women older than 25 years     of age.
AsiaPacific     is expected to grow at a high CAGR in the coming years. As per the cancer     council, 61% of the Australian women are screened for cervical cancer     every two years, out of which around 26% who have been detected throughthe     normal Pap test undergo an early re-screening more often than the     recommended two years of interval.
Some     key players in the market are QiagenN. V., Hologic, Inc., Roche Holding     AG, Abbott Laboratories, and Becton, Dickinson and Company.These market     players are in the process of introducing tests to change the traditional     methods of individual HPV and Pap tests and introducenewer techniques or     devices to improve the efficiency and convenience.
For     instance, in February 2016, Quest acquiredClinical Laboratory Partner’s     outreach laboratory service business. This acquisition is expected to     provide the patients a broader service network with better quality,     affordability, and convenience. 
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/healthcare
Grand View Research has segmented the global HPV testing and Pap test market on the basis of type, application, end-use, and regions: 
HPV Testing and Pap Test Outlook by Type (Revenue, USD Million, 2013 – 2024)
Pap     Test
HPV     Test
HPV Testing and Pap Test Application Outlook (Revenue, USD Million, 2013 – 2024)
Cervical     Cancer
Vaginal     Cancer
HPV Testing and Pap Test End-use Outlook (Revenue, USD Million, 2013 – 2024)
Point-of-Care
Central     Laboratories
Others
HPV Testing and Pap Test Regional Outlook (Revenue, USD Million, 2013 – 2024)
 U.S.
 Canada
 UK
 Germany
 Rest      of Europe
 India
 Japan
 China
 Rest      of Asia Pacific
 Brazil
 Rest      of Latin America
 South      Africa
Access press release of this research report by Grand View Research: http://www.grandviewresearch.com/press-release/global-hpv-test-pap-test-market
About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
For more information: www.grandviewresearch.com
0 notes
Text
Tumblr media
Ascension can be spontaneous, yet most of the time it takes a lot of hard work. Either way a-lot of souls are ascending and engaging in their true purpose at this time. Soul contracts are being dissolved and blueprints being redesigned. Templates are no longer abstract and 3 dimensional, new life, new energy, and new creations are being birthed from the old, indeed there is nothing new under the sun, instead the newness comes from with in, this newness is deeper than the ocean and moser vast than multiverses full of galaxies.
#infinitebeings #newground #expandinguniverse #expandingconsciousness #ascensioncodes #dnasequencies #211122 #122222 #112122 #112222 #231122
7 notes · View notes